High Vs. Low-Intensity Bridging Chemotherapy in Children with Acute Lymphoblastic Leukemia Awaiting Chimeric Antigen Receptor T-Cell Therapy: A Population-Based Study from Ontario, Canada

Conclusions: We demonstrate in our population-based cohort of heavily pre-treated and high-risk patients that initial low-intensity chemotherapy had a very high likelihood of successfully bridging children to CAR-T infusion. Low-intensity bridging regimens were associated with lower rates of toxicity and higher quality of life as indicated by fewer inpatient days. Low-intensity regimens should be considered the first line option in this population.DisclosuresGrupp: Jazz Pharmaceuticals: Consultancy; Adaptimmune: Consultancy; University of Pennsylvania: Patents & Royalties; Novartis Pharmaceuticals Corporation: Consultancy, Research Funding. Maude: Novartis Pharmaceuticals Corporation: Consultancy, Membership on an entity's Board of Directors or advisory committees.

Source: Blood - November 21, 2018 Category: Hematology Authors: Gupta, S., Alexander, S., Zupanec, S., Athale, U., Bassal, M., Edwards, E., Gibson, P. J., Johnston, D., Marjerrison, S., Zorzi, A., Hitzler, J. K., Naqvi, A., Punnett, A., Whitlock, J. A., Grupp, S. A., Maude, S. L., Krueger, J. Tags: 614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: Poster I Source Type: research